Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EPS (Basic) (2023 - 2025)

Immunome (IMNM) has disclosed EPS (Basic) for 3 consecutive years, with -$0.76 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 40.62% year-over-year to -$0.76, compared with a TTM value of -$2.43 through Dec 2025, up 53.0%, and an annual FY2025 reading of -$2.43, up 51.4% over the prior year.
  • EPS (Basic) was -$0.76 for Q4 2025 at Immunome, down from -$0.65 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.35 in Q1 2023 and bottomed at -$4.22 in Q4 2023.
  • Average EPS (Basic) over 3 years is -$1.08, with a median of -$0.62 recorded in 2024.
  • The sharpest move saw EPS (Basic) plummeted 617.14% in 2024, then surged 79.28% in 2025.
  • Year by year, EPS (Basic) stood at -$4.22 in 2023, then skyrocketed by 69.67% to -$1.28 in 2024, then surged by 40.62% to -$0.76 in 2025.
  • Business Quant data shows EPS (Basic) for IMNM at -$0.76 in Q4 2025, -$0.65 in Q3 2025, and -$0.5 in Q2 2025.